Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Who is really a candidate for active surveillance (AS) as opposed to early treatment for prostate cancer that is supposedly localized is not yet well-defined. Indeed, it may not even be possible to come up with any “absolute” guidelines for eligibility for AS based on the diagnostic and prognostic tools we have at this time.
Filed under: Management | Tagged: active surveillance, expectant managemt, outcomes | 4 Comments »
While it has never been categorically proven that adding an oral antiandrogen like flutamide or bicalutamide (Casodex) to injections of LHRH agonists (e.g., leuprolide actetate) improves overall patient survival, there had been little doubt in people’s minds that giving an antiandrogen for a week or two before a first LHRH agonist injection prevented the problem [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, flare, LHRH agonist, testosterone | 1 Comment »
For the serious student of the biological sciences, the idea that the immediate, internal, biological environment can profoundly impact the ability of any type of cell to grow and evolve is hardly new.
Filed under: Uncategorized | Tagged: cancer, cell, development, environment | Leave a Comment »
“Found, the super molecule to kill prostate cancer cells,” trumpeted the MailOnline. And worse still, “A miracle molecule has been discovered that offers the hope of saving men with currently incurable prostate cancer,” screamed the Press Association.
Filed under: Drugs in development | Tagged: F77, hype, MAb, media, monoclonal antibody | 15 Comments »
Nearly 3 months ago, we reported on the publication of a paper by Gat et al. that describes a completely normal way by which very high levels of testosterone could “flood” through the prostate and potentially stimulate the development of prostate cancer.
Filed under: Uncategorized | 26 Comments »
The role of positron emission tomography or PET scanning in the work-up and management of prostate cancer patients is evolving.
Filed under: Diagnosis, Management | Tagged: PET, positron emission tomography | 1 Comment »
As initially reported in The Gray Sheet, an advisory committee to the US Food and Drug Administration (FDA) has suggested that new forms of device-based treatment for organ-confined prostate cancer should have to demonstrate effectiveness and safety in randomized clinical trials compared to active surveillance.
Filed under: Management, Treatment | Tagged: clinical trials, devices | Leave a Comment »
There are some things most doctors just don’t learn in medical school … they just have to have the personal experience. Dr. Staren’s story in the Chicago Sun-Times yesterday is an example (albeit not prostate cancer-specific).
Filed under: Uncategorized | Comments Off
They haven’t tried this on an actual patient yet (or at least, if they have, it hasn’t been reported) but a group at the University of Washington in Seattle is investigating the potential of low-dose, alternating electric current as a possible treatment for early stage prostate cancer.
Filed under: Management, Treatment | Tagged: alternating, current, early stage, electric, Treatment | 3 Comments »
Some prior studies have suggested a relationship between obesity and adverse pathologic features on prostate biopsy and have suggested that obese patients may be at higher risk for prostate cancer-related death after radical prostatectomy. However, other studies have been unable to demonstrate any relationship between obesity and clinical risks from prostate cancer.
Filed under: Diagnosis, Risk | Tagged: obesity, risk, saturation biopsy | 1 Comment »
Prostate Cancer International has been invited to work with a consortium of major prostate cancer centers to get patient feedback on a national, development-stage data monitoring system that will allow prostate cancer patients to track their data over time and compare their outcomes to those of other similar patients. Please help us by giving us your [...]
Filed under: Uncategorized | Comments Off
There are three fairly significant news reports today dealing with the following issues: The relationship between a family history of prostate cancer and age at diagnosis The impact of RALP on selection of surgery as a first-line treatment option The management of ADT-related hot flashes
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: family history, hot flashes, RALP, robot-assisted laparoscopic prostatectomy, Treatment | Leave a Comment »
In a somewhat surprising announcement, Teva Pharmaceuticals — best known as the world’s largest manufacturer and marketer of generic drugs — has acquired the global development and marketing rights to OGX-011 from OncoGenex.
Filed under: Drugs in development | Tagged: OGX-011, OncoGenex, Teva | Leave a Comment »
It has been hoped (at least by some) that a possible use of the prostate cancer gene 3 or PCA3 test — approved in parts of Europe but still in clinical trials in the US – would be as a better tool than PSA tests and annual biopsies to monitor patients on expectant management (active surveillance).
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, expectant management, PCA3, progression | 10 Comments »
In honor of the 18 inches of snow (or so) yesterday in Philadelphia and other parts of the the East Coast, we have turned the “snow” back on for the holidays (but only through January 4). Enjoy … or come and help your sitemaster dig out!
Filed under: Uncategorized | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site